Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

Reliable, high-quality products require innovative analytics and production.

Biosimilars to Drive Modern Manufacturing Approaches

Elizabeth Rivera is a technical services manager at the Life Sciences Division of STERIS Corporation.

Paul Lopolito is a technical services specialist at STERIS, Mentor, OH.

A lifecycle approach can be used to develop GMP-compliant cleaning procedures for continuous manufacturing of solid-dosage pharmaceuticals.

Cleaning Validation in Continuous Manufacturing

Fernando J. Muzzio, PhD, is a professor and the director of the pharmaceutical engineering program at the Department of Chemical and Biochemical Engineering, Rutgers University, 98 Brett Road, Piscataway, NJ 08854-8058, tel. 732.445.3357.

C-SOPS, Department of Chemical and Biochemical Engineering at Rutgers, The State University of New Jersey

Shear-sensitive ingredients in a tableting formulation experience different conditions in a batch tumble blender than they would in a continuous paddle blender.

Lubrication in Continuous Tubular Powder Blenders

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

A dissolution method should have adequate discriminatory power to detect formulation changes that affect the dissolution rate of a drug product.

Dissolution Testing

A variety of strategies have been employed to deliver proteins and peptides in improved parenteral formulations and/or via noninvasive routes.

Advances in Delivering Protein and Peptide Therapeutics

Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.

Astellas to Acquire Ganymed

The biosimilar pathway permits licensure based on less than full clinical data.

FDA Advises Limited Clinical Testing for Biosimilars

Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.

Oxford Genetics Secures GBP1 Million Investment for Gene Therapy Technologies

The collaboration follows the signing of a cooperative research agreement between Sanofi Pasteur, Fiocruz, and WRAIR.

Sanofi Pasteur Collaborates with WRAIR, Fiocruz on Zika Vaccine Development

FDA’s new Office of Tissues and Advanced Therapies will oversee a growing range of cellular and genetic products.